Guaifenesin History

Guaifenesin was aboriginal accustomed by the Food and Pharmaceutical Administering (FDA) in 1952. Although ahead accounted "Generally Regarded as Safe" in its aboriginal approval, the Pharmaceutical accustomed a New Pharmaceutical Appliance for the extended-release version, which won approval on July 12, 2002.

Similar medicines acquired from the guaiac timberline were in use as a all-encompassing antidote by American aboriginal peoples if campaign accomplished North America in the 16th century.

Guaiacum has a bounded analeptic action which is sometimes advantageous in abscessed throat. The adhesive is acclimated in abiding gout and rheumatism, whilst the copse is an additive in the admixture concentrated band-aid of sarsaparilla, which was aforetime abundant acclimated as an accession in syphilis.

Because of this, the FDA again issued belletrist to added manufacturers of timed-release guaifenesin to stop business their crooked versions, abrogation Adams Respiratory Therapeutics in ascendancy of the market. Adams was afterwards acquired by Reckitt Benckiser, based on the backbone of the business generated by Adams' Mucinex brand.

To learn more: Guaifenesin

from: Pharmaceutical Ingredients